Latest News

SGLT2 inhibitors, GLP-1 RAs are effective, but costly in T2D

Publish date: July 10, 2019
By
Randy Dotinga
Katie Lennon

 

Recommended Reading

Aggressive lowering of LDL cholesterol: Is it a good idea?
MDedge Internal Medicine
Do black patients with type 2 diabetes gain cardiac benefit from the SGLT2 and GLP-1 drugs?
MDedge Internal Medicine
FDA issues warning on insulin pump cybersecurity weakness
MDedge Internal Medicine
Surprise! High-fat dairy may protect against metabolic syndrome
MDedge Internal Medicine
To help patients stay on diabetes regimens: Communicate, educate, and use technology
MDedge Internal Medicine
CAROLINA findings reaffirm linagliptin’s safety, free glimepiride of CV-risk stigma
MDedge Internal Medicine
New findings cast more doubt on ‘fat-but-fit’ theory
MDedge Internal Medicine
VOC-sniffing necklace may support early detection of hypoglycemia
MDedge Internal Medicine
Mortality caused by chronic liver disease in setting of diabetes continues to rise
MDedge Internal Medicine
Metformin linked to lower dementia risk in black patients
MDedge Internal Medicine